References
- European Centre for Disease Prevention and Control. Factsheet about seasonal influenza; 2018 [accessed 2018 May]. https://ecdc.europa.eu/en/seasonal-influenza/facts/factsheet.
- Iuliano AD, Roguski KM, Chang HH, Muscatello DJ, Palekar R, Tempia S, Cohen C, Gran JM, Schanzer D, Cowling BJ, et al. Estimates of global seasonal influenza-associated respiratory mortality: a modelling study. Lancet. 2018;391(10127):1285–300. doi:10.1016/S0140-6736(17)33293-2.
- World Health Organization. Burden of disease; [accessed 2018 May]. http://www.who.int/influenza/surveillance_monitoring/bod/en/.
- World Health Organization. Fact sheets - Influenza (Seasonal); [accessed 2018 Sep]. http://www.who.int/news-room/fact-sheets/detail/influenza- (seasonal).
- World Health Organization. WHO recommendations on the composition of influenza virus vaccines; [accessed 2018 May]. http://www.who.int/influenza/vaccines/virus/recommendations/en/.
- Levi M, Sinisgalli E, Lorini C, Santomauro F, Chellini M, The BP. “Fluad case” in Italy: could it have been dealt differently? Hum Vacc Immunother. 2017;13(2):379–84. doi:10.1080/21645515.2017.1264738.
- Rosselli R, Martini M, Bragazzi NL, Watad A. The public health impact of the so-called “fluad effect” on the 2014/2015 influenza vaccination campaign in italy: ethical implications for health-care workers and health communication practitioners. Adv Exp Med Biol. 2017;973:125–34. doi:10.1007/5584_2017_39.
- Bardage C, Persson I, Ortqvist A, Bergman U, Ludvigsson JF, Granath F. Neurological and autoimmune disorders after vaccination against pandemic influenza A (H1N1) with a monovalent adjuvanted vaccine: population based cohort study in Stockholm, Sweden. BMJ (Clinical Research Ed). 2011;343:d5956. doi:10.1136/bmj.d5956.
- Borg JJ, Aislaitner G, Pirozynski M, Mifsud S. Strengthening and rationalizing pharmacovigilance in the EU: where is Europe heading to? A review of the new EU legislation on pharmacovigilance. Drug Saf. 2011;34(3):187–97. doi:10.2165/11586620-000000000-00000.
- European Medicines Agency. Interim guidance on enhanced safety surveillance for seasonal influenza vaccines in the EU. London; 2014 [accessed 2018 Nov]. https://www.ema.europa.eu/documents/scientific-guideline/interim-guidance-enhanced-safety-surveillance-seasonal-influenza-vaccines-eu_en.pdf.
- European Medicines Agency. Guideline on good pharmacovigilance practices (GVP). Product- or Population-Specific Considerations I: Vaccines for prophylaxis against infectious diseases. EMA/488220/2012; 2013 [accessed 2018 Sep]. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2013/12/WC500157839.pdf.
- European Medicines Agency. Guideline on good pharmacovigilance practices (GVP). Module VIII – Post-authorization safety studies (Rev 3). EMA/813938/2011 Rev 3; 2013 [accessed June 2018]. http://www.ema.europa.eu/docs/en_GB/document_library/_guideline/2012/06/WC500Scientific.pdf.
- de Lusignan S. Codes, classifications, terminologies and nomenclatures: definition, development and application in practice. Inform Prim Care. 2005;13:65–70.
- de Lusignan S, Hague N, van Vlymen J, Kumarapeli P. Routinely-collected general practice data are complex, but with systematic processing can be used for quality improvement and research. Inform Prim Care. 2006;14:59–66.
- NHS England. Enhanced Service Specification: Seasonal influenza and pneumococcal polysaccharide vaccination programme 2015/16; 2015.
- Public Health England. Seasonal influenza vaccine uptake in GP patients: winter season 2017 to 2018: final data for 1 September 2017 to 31 January 2018; 2018 [accessed 2018 Nov]. https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/710416/Seasonal_influenza_vaccine_uptake_in_GP_patients_winter_season_2017_to_2018.pdf.
- de Lusignan S, Dos Santos G, Correa A, Haguinet F, Yonova I, Lair F, Byford R, Ferreira F, Stuttard K, Chan T. Post-authorisation passive enhanced safety surveillance of seasonal influenza vaccines: protocol of a pilot study in England. BMJ Open. 2017;7:5. doi:10.1136/bmjopen-2016-015469.
- de Lusignan S, Dos Santos G, Byford R, Schuind A, Damaso S, Shende V, McGee C, Yonova I, Ferreira F. Enhanced safety surveillance of seasonal quadrivalent influenza vaccines in english primary care: interim analysis. Adv Ther. 2018;35(8):1199–214. doi:10.1007/s12325-018-0747-4.
- Electronic Medicines Compendium. GlaxoSmithKline UK. Fluarix Tetra Summary Product Characteristics; 2018 [accessed 2018 Nov]. https://www.medicines.org.uk/emc/product/3021/smpc.
- Clothier HJ, Crawford NW, Russell M, Kelly H, Buttery JP. Evaluation of ‘SAEFVIC’, A pharmacovigilance surveillance scheme for the spontaneous reporting of adverse events following immunisation in Victoria, Australia. Drug Saf. 2017;40(6):483–95. doi:10.1007/s40264-017-0520-7.
- Clothier HJ, Hosking L, Crawford NW, Russell M, Easton ML, Quinn JA, Buttery JP. Bacillus Calmette-Guerin (BCG) vaccine adverse events in Victoria, Australia: analysis of reports to an enhanced passive surveillance system. Drug Saf. 2015;38(1):79–86. doi:10.1007/s40264-014-0248-6.
- Kemmeren JM, van der Maas NAT, de Melker HE. Parental reports of adverse events following simultaneously given dT-IPV and MMR vaccines in healthy 9-year-old children. Eur J Pediatr. 2011;170(3):339–45. doi:10.1007/s00431-010-1294-4.
- Regan AK, Tracey L, Gibbs R. Post-marketing surveillance of adverse events following immunization with inactivated quadrivalent and trivalent influenza vaccine in health care providers in Western Australia. Vaccine. 2015;33(46):6149–51. doi:10.1016/j.vaccine.2015.10.005.
- van Balveren-Slingerland L, Kant A, Härmark L. Web-based intensive monitoring of adverse events following influenza vaccination in general practice. Vaccine. 2015;33(19):2283–88. doi:10.1016/j.vaccine.2015.03.014.
- Newes-Adeyi G, Greece J, Bozeman S, Walker DK, Lewis F, Gidudu J. Active surveillance for influenza vaccine adverse events: the integrated vaccine surveillance system. Vaccine. 2012;30(6):1050–55. doi:10.1016/j.vaccine.2011.12.041.
- Public Health England. Flu plan winter 2016/17; 2016 [accessed 2018 June]. https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/525967/Annual_flu_plan_2016_to_2017.pdf.
- Correa A, Hinton W, McGovern A, van Vlymen J, Yonova I, Jones S, de Lusignan S. Royal college of general practitioners research and surveillance centre (RCGP RSC) sentinel network: a cohort profile. BMJ Open. 2016;6:4. doi:10.1136/bmjopen-2016-011092.
- de Lusignan S, Correa A, Smith GE, Yonova I, Pebody R, Ferreira F, Elliot AJ, Fleming D. RCGP research and surveillance centre: 50 years’ surveillance of influenza, infections, and respiratory conditions. Br J Gen Pract. 2017;67(663):440–41. doi:10.3399/bjgp17X692645.
- Clinical Informatics and Health Outcomes Research Group. Post-authorisation passive enhanced safety surveillance of seasonal influenza vaccines: pilot study in England. Guildford (UK): University of Surrey; 2017. [accessed 2018 June]. http://www.ema.europa.eu/docs/en_GB/document_library/_guideline/2012/06/WC500Scientific.pdf.
- Tippu Z, Correa A, Liyanage H, Burleigh D, McGovern A, Van Vlymen J, Jones S, De Lusignan S. Ethnicity recording in primary care computerised medical record systems: an ontological approach. J Innov Health Inform. 2017;23(4):920. doi:10.14236/jhi.v23i4.920.
- Jordan H, Roderick P, Martin D. The index of multiple deprivation 2000 and accessibility effects on health. J Epidemiol Community Health. 2004;58:250–57.
- de Lusignan S, Hoghton M, Rafi I. Flu vaccination by pharmacists leads to suboptimal medical records. BMJ (Clinical Research Ed). 2017;359:j5084. doi:10.1136/bmj.j5084.
- Liang KY, Zeger SL. Longitudinal data analysis using generalized linear models. Biometrika. 1986;73:13–22. doi:10.1093/biomet/73.1.13.
- Clopper CJ, Pearson ES. The use of confidence or fiducial limits illustrated in the case of binomial. Biometrika. 1934;26:404–13. doi:10.1093/biomet/26.4.404.